Ipamorelin: Evidence, Legal Status & Clinics

Ipamorelin is a growth-hormone secretagogue, often paired with CJC-1295. What the evidence and 2026 legal status say, why it's WADA-banned in sport, and what to ask clinics that reference it. This page is informational and does not diagnose, prescribe, or recommend therapies.

Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.

Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.

Common contexts

  • Often appears in clinic listings focused on growth hormone support, recovery, or performance goals.
  • Providers may combine ipamorelin with other peptides in broader optimisation protocols.
  • Directory listings typically frame it within clinician-led rather than cosmetic-only pathways.

Safety information

  • Suitability depends on medical history, goals, and the clinic's prescribing framework.
  • Ask about evidence quality, dosing rationale, and how progress or adverse effects will be monitored.
  • A reputable clinic should explain why ipamorelin is being considered instead of simpler alternatives.

Quick summary

  • Ipamorelin is a growth-hormone secretagogue studied for prompting the body's own growth-hormone release, often discussed alongside CJC-1295.
  • It is not an approved medicine: it is not FDA-approved for any human use, and in the UK the MHRA treats it as unlicensed.
  • Its US compounding status changed during 2026 and remains in flux (part of a broader peptide reclassification), so confirm current access with a clinician.
  • It is prohibited in sport at all times by WADA as a growth-hormone secretagogue.
  • Clinics reference it in performance, recovery, anti-aging, and longevity contexts, usually within a broader plan.
  • This page is informational only — it does not diagnose, prescribe, recommend ipamorelin, or provide dosing guidance.

Evidence at a glance

A scannable summary of what the current research and UK/US regulatory position actually show. Educational only — not medical advice, and no dosing guidance.

Evidence
Limited — long-term human evidence is lacking, and risks in healthy people are not well characterised. Product quality varies across an unregulated supply chain.
Human data
Insufficient. No large human trials establishing efficacy or long-term safety.
UK regulatory status
Not a licensed UK medicine — the MHRA treats it as unlicensed.
US regulatory status
Not FDA-approved for any human therapeutic use. Its US compounding status shifted during 2026 as part of a broader peptide reclassification and remains an area of change — confirm current access directly.
Anti-doping (sport)
On the WADA prohibited list — tested athletes should treat it as banned.

Last reviewed 13 August 2026. Regulatory status can change — always confirm the current position with a qualified clinician.

Clear intro

Ipamorelin pages attract users comparing growth-hormone and recovery options. The strongest clinics explain the evidence limits, the WADA ban, and the shifting regulatory status honestly rather than marketing it as a simple upgrade.

Who this is for

This page is useful for people researching performance, recovery, hormone-optimisation, and longevity clinics that reference ipamorelin — often alongside CJC-1295.

What to ask before choosing a clinic

  • Why ipamorelin, and why combined with CJC-1295 if it is?
  • What sourcing, supervision, and monitoring are included?
  • What does the evidence realistically support, and what is the current legal status?

Pricing and red flags

Ipamorelin pricing usually sits within a broader programme rather than as a standalone figure. Compare the oversight and monitoring included, not just the headline cost.

  • Guaranteed growth-hormone, anti-aging, or body-composition results.
  • No discussion of evidence limits, regulatory status, or the WADA ban.
  • No baseline assessment or monitoring before a protocol is discussed.

What is Ipamorelin?

Ipamorelin is a synthetic peptide that acts as a growth-hormone secretagogue, prompting the pituitary gland to release more of the body's own growth hormone. It is often discussed alongside CJC-1295, which works on a complementary pathway. Ipamorelin is not an approved medicine: it is not FDA-approved for any human therapeutic use, and in the UK the MHRA treats it as unlicensed. Its US compounding status shifted during 2026 as part of a broader reclassification of peptides and remains an area of change, so current access should be confirmed directly. It is also on the WADA prohibited list. On clinic directories it appears in performance, recovery, anti-aging, and longevity contexts.

How it works

Ipamorelin mimics ghrelin to stimulate growth-hormone release, and is often described as relatively selective compared with some older secretagogues. As with the other growth-hormone peptides, most of the supporting information comes from limited research rather than large long-term human trials, so mechanism descriptions are not the same as proven outcomes. For someone comparing clinics, the useful questions are about supervision, monitoring, sourcing, and why ipamorelin (often with CJC-1295) is being considered.

Typical use cases

  • Performance and recovery discussions, frequently combined with CJC-1295.
  • Anti-aging and hormone-optimisation contexts framed around growth-hormone support.
  • Body-composition and sleep-related pathways within a broader, clinician-led plan.

Cost overview

Ipamorelin is usually bundled into a broader hormone, performance, or recovery programme — often with CJC-1295 — so clinician involvement, monitoring, and sourcing transparency matter more than the headline figure. See the peptide therapy cost guide.

What to expect from clinics

  • A credible clinic should be clear that ipamorelin is not an approved medicine, is banned in tested sport, and has limited long-term human evidence.
  • Expect clear explanation of sourcing, supervision, monitoring, and why it is being combined with other peptides such as CJC-1295.
  • Be cautious of providers presenting it as risk-free or guaranteeing growth-hormone or body-composition results.

Safety considerations

Because ipamorelin is not an approved medicine and long-term human safety data is limited, its risks are not well characterised, and product quality varies across an unregulated supply chain. It is also banned in tested sport, and its compounding status has been changing in 2026. It should only be considered with a licensed clinician who can explain the evidence limits, regulatory status, and risks. This page does not recommend ipamorelin and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.

Frequently asked questions about Ipamorelin

Is ipamorelin FDA-approved?

No. Ipamorelin is not FDA-approved for any human therapeutic use. Its US compounding status changed during 2026 as part of a broader peptide reclassification and remains in flux, so confirm current access with a clinician.

What is ipamorelin used for?

In clinics it is usually discussed within performance, recovery, anti-aging, and longevity programmes aimed at supporting the body's own growth-hormone output, often alongside CJC-1295. Evidence in healthy adults is limited.

Why is ipamorelin combined with CJC-1295?

They act on complementary parts of the growth-hormone pathway, so clinics often discuss them together. Combining them does not make either one approved or risk-free — the same evidence and safety cautions apply.

Is ipamorelin banned in sport?

Yes. Ipamorelin is on the WADA prohibited list as a growth-hormone secretagogue, prohibited at all times. Any athlete subject to testing should treat it as banned.

Is ipamorelin legal in the UK?

Ipamorelin is not licensed as a medicine in the UK; the MHRA treats it as unlicensed. Any clinical use sits under unlicensed-medicine rules and the prescribing clinician's responsibility.

Does Peptide Clinic Finder sell or recommend ipamorelin?

No. Peptide Clinic Finder is an informational directory. We do not sell ipamorelin, provide medical advice, or recommend its use — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.

Related comparisons: CJC-1295 vs Ipamorelin, MK-677 vs Ipamorelin, Ipamorelin vs Sermorelin, BPC-157 vs Ipamorelin.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Related Ipamorelin pages

Move from peptide research into clinic comparisons, guides, and matching.

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering Ipamorelin

The Catalyst Clinic logo
RecommendedVerified

The Catalyst Clinic

London, United Kingdom5.05.0 out of 5

Doctor-led peptide advisory consultations in central London. Every protocol is built around comprehensive bloodwork and personally led by Dr Ethan Hausman-Marquis, who reports a PhD from the Karolinska Institute, with compounds sourced from GMP-certified, EMA-regulated pharmacies.

  • Google 5.0 (48)
Doctor-led clinical governance

From £600

View Profile
LiveNow Longevity logo
RecommendedVerified

LiveNow Longevity

Las Vegas, NV, USA

LiveNow Longevity is a physician-led longevity and peptide clinic in Las Vegas — built on a simple promise: transparent medicine with no markup on your meds. Founded by board-certified neurologist Dr. Charles Kamen, MD, every patient starts with an $88 medical evaluation including baseline labs. From there, care can include peptide therapy, anti-aging treatments, GLP-1 weight loss (semaglutide and tirzepatide), NAD+ therapy, hormone optimization, and recovery support. In person in Las Vegas, or via telehealth across Nevada.

  • Doctor-led
Physician-led by Dr. Charles Kamen, MD
View Profile
Menon Health logo
FeaturedVerified

Menon Health

London, United Kingdom

Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practise within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.

  • Google 3.7 (3)
GMC-registered physicians

From £195

View Profile
Levitas Clinic Mayfair London logo

Levitas Clinic Mayfair London

London, United Kingdom

Levitas Clinic Mayfair London is a specialist clinic listed on Peptide Clinic Finder in London, UK. Listed services are based on approved review evidence. It holds a 5.0-star Google rating from 105 reviews.

  • Google 5.0 (105)
View Profile

Explore clinics by city

What to do next

Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.

Next step

Explore suitable clinics

Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and programme structure than by peptide name alone.

Map preview
Mapbox map preview

For clinics

Are you a clinic?

Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.